{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:53:31Z","timestamp":1790765611053,"version":"4.1.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ferrer Internacional"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.2217\/fmb-2019-0089","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T08:08:14Z","timestamp":1559030894000},"page":"773-787","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Microbiological Profile of Ozenoxacin"],"prefix":"10.1080","volume":"14","author":[{"given":"Ian","family":"Morrissey","sequence":"first","affiliation":[{"name":"IHMA Europe S\u00e0rl,\rMonthey,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda,Hospital Universitario Ram\u00f3n y Cajal & Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS),\rMadrid,\rSpain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI),Instituto de Salud Carlos III,\rMadrid,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI),Instituto de Salud Carlos III,\rMadrid,\rSpain"},{"name":"Microbiology Service,Biomedical Diagnostic Center,Hospital Clinic,University of Barcelona,\rSpain"},{"name":"Institute of Global Health of Barcelona (ISGlobal),\rBarcelona,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Gargallo-Viola","sequence":"additional","affiliation":[{"name":"ABAC Therapeutics,\rBarcelona,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilonka","family":"Zsolt","sequence":"additional","affiliation":[{"name":"Medical Department,Ferrer Internacional,\rBarcelona,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Garcia-Castillo","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda,Hospital Universitario Ram\u00f3n y Cajal & Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS),\rMadrid,\rSpain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI),Instituto de Salud Carlos III,\rMadrid,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuly","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Institute of Global Health of Barcelona (ISGlobal),\rBarcelona,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"e_1_3_3_3_1","first-page":"1187","volume-title":"In: Dermatology (3rd Edition)","author":"Bolognia J","year":"2012","unstructured":"Bolognia J , JorizzoJL , SchafferJV. Bacterial diseases. In: Dermatology (3rd Edition). BologniaJ, JorizzoJL, SchafferJV (Eds). Saunders, PA, USA,1187\u20131189 (2012)."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7457.95"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/978-3-540-29316-3_12","volume-title":"Braun-Falco's Dermatology.","author":"Abeck D","year":"2009","unstructured":"Abeck D . Staphylococcal and streptococcal diseases. In: Braun-Falco's Dermatology.BurgdorfW, PlewigG, WolffHH, LandthalerM (Eds). Springer-Verlag, Berlin, Heidelberg, Germany, 114\u2013139 (2009)."},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/978-3-540-29316-3_109","volume-title":"Braun-Falco\u00b4s Dermatology.","author":"Garbe C","year":"2009","unstructured":"Garbe C , WolfG. Topical therapy. In: Braun-Falco\u00b4s Dermatology.BurgdorfW, PlewigG, WolffHH, LandthalerM (Eds). Springer-Verlag, Berlin, Heidelberg, Germany, 1549\u20131572 (2009)."},{"key":"e_1_3_3_7_1","article-title":"Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health","author":"Edge R","year":"2017","unstructured":"Edge R , Arg\u00e1ezC (Eds). Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. CADTH Rapid Response Reports (2017). www.cadth.ca\/sites\/default\/files\/pdf\/htis\/2017\/RC0851%20Topical%20Antibiotics%20for%20Impetigo%20Final.pdf","journal-title":"CADTH Rapid Response Reports"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.455"},{"key":"e_1_3_3_9_1","unstructured":"Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX\u2122 (ozenoxacin cream 1%) (2019). https:\/\/www.newswire.ca\/news-releases\/cipher-pharmaceuticals-receives-health-canada-approval-of-ozanex-ozenoxacin-cream-1-621597383.html"},{"key":"e_1_3_3_10_1","unstructured":"MHRA . Summary of product characteristics: ozadub 10 mg\/g cream. Ozenoxacin (2019). www.mhra.gov.uk\/spc-pil\/?subsName=OZENOXACIN&pageID=SecondLevel"},{"key":"e_1_3_3_11_1","unstructured":"Health Products Regulatory Authority . Summary of product characteristics: dubine 10 mg\/g cream. Ozenoxacin (2019). https:\/\/www.hpra.ie\/homepage\/medicines\/medicines-information\/find-a-medicine\/results?query=OZENOXACIN&field=ACTIVESUBSTANCES"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1573671"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.78"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1103"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-13"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2017-0289"},{"key":"e_1_3_3_17_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI) . Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline. CLSI Document M45-A. CLSI PA USA 19087\u20131898 (2006)."},{"key":"e_1_3_3_18_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI) . Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard \u2013 Eighth Edition. CLSI Document M7-A8. CLSI PA USA 19087\u20131898 (2009)."},{"key":"e_1_3_3_19_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI) . Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. CLSI PA USA 19087\u20131898 (2010)."},{"key":"e_1_3_3_20_1","unstructured":"British Society for Antimicrobial Chemotherapy . BSAC Methods for Antimicrobial Susceptibility Testing. Version 9.1 March 2010 (2010). http:\/\/bsac.org.uk\/wp-content\/uploads\/2012\/02\/Version_9.1_March_2010_final-v2.pdf"},{"key":"e_1_3_3_21_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI) . Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement. CLSI Document M100-S21 PA USA (2011)."},{"key":"e_1_3_3_22_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing . Mupirocin: rationale for the clinical breakpoints version 1.0 2010. www.eucast.org"},{"key":"e_1_3_3_23_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing . Fusidic acid: rationale for the clinical breakpoints version 1.0 2010. www.eucast.org"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-014-0175-8"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/499365"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01984-06"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm531"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0771"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq094"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.13.14.08084-en"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12223-008-0056-4"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt085"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00406-17"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.03.006"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.03.004"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198632050-00002"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.suppl_B.1"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2019-0089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:38:23Z","timestamp":1719124703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2019-0089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.2217\/fmb-2019-0089"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2019-0089","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}